Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Hétérogénéité Des Tumeurs Rhabdoides : Approches en " Cellules Uniques " Pour Identifier Des Cibles thérapeutiques

ID
Name
APHP200122
Description
The aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment.
Trial arms
Trial start
2022-03-31
Estimated PCD
2025-04-01
Trial end
2025-04-01
Status
Recruiting
Treatment
analyzes in singles cells
genome expression analyzes in single cells
Arms:
ATRT
Size
15
Primary endpoint
Intra-tumor heterogeneity
Inclusion
Eligibility criteria
Inclusion Criteria: * Aged 0-17 years old * having a rhabdoid tumor according to clinical and radiological features Or likely having a rhabdoid tumor according to clinical and radiological features * surgical resection in standard care * sufficient material for both diagnosis and experimental procedures * parents' agreement
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Tumor samples'}, 'enrollmentInfo': {'count': 15, 'type': 'ESTIMATED'}}
Updated at
2024-03-27

1 organization

1 product

1 indication

Organization
Assistance Publique - Hôpitaux de Paris
Product
Analyzes in Singles Cells
Indication
ATRT